Siam Commercial Bank Ventures

Siam Commercial Bank Ventures, branded SCB 10X, is the technology and venture investment unit of Thailand’s Siam Commercial Bank, writing Series A, Series B, and growth-stage checks in the $5M to $25M range. The unit’s mandate spans digital, fintech, AI, and adjacent sectors, with healthcare relevance concentrated in digital health platforms, AI applications targeting Thai or regional clinical and insurance use cases, and tech-enabled care that can integrate with the broader SCB ecosystem. The right counterparty is a Series A or B-stage Thai or regional Southeast Asian healthcare company with credible product-market fit, a strategic angle that touches financial services, insurance, or banking infrastructure, and the ambition to operate at SCB’s institutional cadence. Founders raising sub-$5M Seed rounds, building biotech, or pursuing pure consumer wellness should look at earlier-stage or specialist investors. SCB 10X has been one of the more public corporate venture units in Southeast Asia, with stated interest in AI, blockchain, and emerging technologies, and its strategic agenda includes the bank’s broader digital transformation. Healthcare and AI founders should think about how their product touches insurance, payments, identity, or data infrastructure that SCB cares about, because the strategic narrative shapes deal velocity. Geographic advantage is access to Thai distribution, SCB’s customer base, and broader SCBX group resources, plus connectivity into the regional Southeast Asian corporate network. The flip side is corporate cadence: pilots and procurement run on bank timelines, and IT and risk reviews are deeper than typical financial venture diligence. Best entry is via SCB 10X’s investment team, the bank’s open-innovation programs, or warm referrals from CEOs who have actually executed pilots inside SCB. Cold inbound is read but conversion correlates with strategic clarity. Lead the pitch with the strategic fit, audited financials, and the pilot or commercial relationship you propose. Be explicit about Thai data residency, PDPA compliance, and how AI quality is monitored in production for any clinical-adjacent product. Caveats: negotiate exclusivity, MFN, and right-of-first-refusal language carefully. Confirm whether the check is balance-sheet or fund-structured, and ask about reserves and follow-on behavior. Corporate venture leadership and strategic priorities can shift, so reference checks with current portfolio CEOs on responsiveness, value realized, and behavior through leadership transitions are particularly important. Used appropriately, SCB 10X is one of the more strategic Thai partners for healthcare and AI founders with a credible financial services angle; for founders without that angle, it is a less natural fit.